Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve CapGlobeNewsWire • 01/18/24
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023GlobeNewsWire • 01/04/24
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025GlobeNewsWire • 01/04/24
Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023GlobeNewsWire • 10/18/23
Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, OhioGlobeNewsWire • 08/21/23
Axogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023GlobeNewsWire • 07/26/23
Wall Street Analysts Think AxoGen (AXGN) Could Surge 69.62%: Read This Before Placing a BetZacks Investment Research • 06/09/23